{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:09:19Z","timestamp":1791245359920,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>People with HIV (PWH) using antiretroviral therapy (ART) remain at increased risk for infections such as community-acquired pneumonia (CAP) and herpes zoster (HZ), for which vaccinations are recommended. However, these recommendations do not consider the combined effects of age, CD4 count, and duration of ART on infection risk. We assessed how these factors influence CAP and HZ incidence to better tailor vaccination strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used data from a nationwide cohort study including all PWH aged \u226518 years in care between 2010 and 2023. All documented CAP and HZ episodes were included, and incidence rates were calculated per 1000 person-years of follow-up (PYFU), stratified by age, CD4 count, and ART duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Community-acquired pneumonia and herpes zoster incidence rates were highest in PWH with CD4 \u2264 200 cells\/\u00b5L, ranging from 34 to 107\/1000 PYFU for CAP and 9 to 63\/1000 PYFU for HZ, depending on age. In those with CD4 \u2265 500 cells\/\u00b5L and \u22651 year on ART, incidence rates ranged from 5 to 20\/1000 PYFU for CAP and 4 to 5\/1000 PYFU for HZ, depending on age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Incidence rates are the highest in PWH with CD4 counts \u2264200 cells\/\u00b5L and\/or not on ART, whereas PWH with CD4 counts \u2265500 and \u22651 year on ART have a risk of CAP and HZ comparable to that of the general population. These findings support aligning vaccine recommendations for PWH on long-term suppressive ART with immune reconstitution with those for the general population, while HIV-specific vaccination strategies may remain most relevant for individuals with virological failure and\/or poor immune reconstitution.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf686","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T13:02:30Z","timestamp":1765630950000},"page":"997-1006","source":"Crossref","is-referenced-by-count":1,"title":["Incidence of Community-acquired Pneumonia and Herpes Zoster in People With HIV Based on CD4 Count and Age in the Current Antiretroviral Therapy Era: A Longitudinal Cohort Study"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1873-2520","authenticated-orcid":false,"given":"Elsemieke","family":"te Linde","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2066-8115","authenticated-orcid":false,"given":"Ferdinand W N M","family":"Wit","sequence":"additional","affiliation":[{"name":"Stichting HIV Monitoring , Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam UMC Location University of Amsterdam, Department of Infectious Diseases, Amsterdam Institute for Immunology and Infectious Diseases , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5601-4207","authenticated-orcid":false,"given":"Berend J","family":"van Welzen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-6217","authenticated-orcid":false,"given":"Abraham","family":"Goorhuis","sequence":"additional","affiliation":[{"name":"Amsterdam UMC Location University of Amsterdam, Department of Infectious Diseases, Amsterdam Institute for Immunology and Infectious Diseases , Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam UMC Location University of Amsterdam, Center for Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam Institute for Immunology and Infectious Diseases , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert-Jan","family":"Hassing","sequence":"additional","affiliation":[{"name":"Rijnstate Hospital Arnhem, Department of Internal Medicine , Arnhem ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6224-7947","authenticated-orcid":false,"given":"Hanna K","family":"de Jong","sequence":"additional","affiliation":[{"name":"Amsterdam UMC Location University of Amsterdam, Center for Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam Institute for Immunology and Infectious Diseases , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1281-473X","authenticated-orcid":false,"given":"Johanneke","family":"Kleinnijenhuis","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Medical Center Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9153-8196","authenticated-orcid":false,"given":"Steven F L","family":"van Lelyveld","sequence":"additional","affiliation":[{"name":"Spaarne Gasthuis, Department of Internal Medicine , Hoofddorp\/Haarlem ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4962-4792","authenticated-orcid":false,"given":"Els","family":"van Nood","sequence":"additional","affiliation":[{"name":"Erasmus Medical Center, Department of Internal Medicine and Medical Microbiology and Infectious Diseases , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Verbon","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8290-6425","authenticated-orcid":false,"given":"Marc","family":"van der Valk","sequence":"additional","affiliation":[{"name":"Stichting HIV Monitoring , Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam UMC Location University of Amsterdam, Department of Infectious Diseases, Amsterdam Institute for Immunology and Infectious Diseases , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke H W","family":"Bruns","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"2026070722322840300_ciaf686-B1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3390\/v11030200","article-title":"Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART","volume":"11","author":"Zicari","year":"2019","journal-title":"Viruses"},{"key":"2026070722322840300_ciaf686-B2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/cid\/ciz728","article-title":"Incidence and risk factors for invasive pneumococcal disease and community-acquired pneumonia in human immunodeficiency virus-infected individuals in a high-income setting","volume":"71","author":"Garcia Garrido","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026070722322840300_ciaf686-B3","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1086\/430356","article-title":"Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995\u20132000","volume":"191","author":"Heffernan","year":"2005","journal-title":"J Infect Dis"},{"key":"2026070722322840300_ciaf686-B4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/QAI.0b013e318266cd3c","article-title":"Herpes zoster among persons living with HIV in the current antiretroviral therapy era","volume":"61","author":"Blank","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026070722322840300_ciaf686-B5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/01.qai.0000178408.62675.b0","article-title":"The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era","volume":"40","author":"Gebo","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026070722322840300_ciaf686-B6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/cid\/cit165","article-title":"Decreasing incidence of herpes zoster in the highly active antiretroviral therapy era","volume":"57","author":"Moanna","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2026070722322840300_ciaf686-B7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/1471-2334-10-230","article-title":"Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study","volume":"10","author":"Gialloreti","year":"2010","journal-title":"BMC Infect Dis"},{"key":"2026070722322840300_ciaf686-B8","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1186\/s12879-020-05648-6","article-title":"Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009\u20132014","volume":"20","author":"Munoz-Quiles","year":"2020","journal-title":"BMC Infect Dis"},{"key":"2026070722322840300_ciaf686-B9","author":"Behandelaren NVvH"},{"key":"2026070722322840300_ciaf686-B10","author":"European AIDS Clinical Society"},{"key":"2026070722322840300_ciaf686-B11","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae479","article-title":"Primary care guidance for providers of care for persons with human immunodeficiency virus: 2024 update by the HIV Medicine Association of the Infectious Diseases Society of America","author":"Horberg","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026070722322840300_ciaf686-B12","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"2026070722322840300_ciaf686-B13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.rmed.2018.02.007","article-title":"Burden of pneumococcal community-acquired pneumonia in adults across Europe: a literature review","volume":"137","author":"Torres","year":"2018","journal-title":"Respir Med"},{"key":"2026070722322840300_ciaf686-B14","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1080\/21645515.2020.1847582","article-title":"A systematic literature review of herpes zoster incidence worldwide","volume":"17","author":"van Oorschot","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"2026070722322840300_ciaf686-B15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1469-0691.2012.03971.x","article-title":"Vaccination of immunocompromised patients","volume":"18 Suppl 5","author":"Ljungman","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2026070722322840300_ciaf686-B16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.autrev.2011.05.015","article-title":"Immunization in the adult immunocompromised host","volume":"11","author":"Lobermann","year":"2012","journal-title":"Autoimmun Rev"},{"key":"2026070722322840300_ciaf686-B17","author":"LCI-RIVM"},{"key":"2026070722322840300_ciaf686-B18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.tmaid.2018.05.016","article-title":"Incidence of invasive pneumococcal disease in immunocompromised patients: a systematic review and meta-analysis","volume":"24","author":"van Aalst","year":"2018","journal-title":"Travel Med Infect Dis"},{"key":"2026070722322840300_ciaf686-B19","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.vaccine.2015.11.048","article-title":"Risk and outcomes of invasive pneumococcal disease in adults with underlying conditions in the post-PCV7 era, the Netherlands","volume":"34","author":"Wagenvoort","year":"2016","journal-title":"Vaccine"},{"key":"2026070722322840300_ciaf686-B20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged &gt;\/=19 years: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022","volume":"71","author":"Anderson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026070722322840300_ciaf686-B21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s15010-013-0550-8","article-title":"Incidence of herpes zoster in patients with altered immune function","volume":"42","author":"Chen","year":"2014","journal-title":"Infection"},{"key":"2026070722322840300_ciaf686-B22","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1093\/cid\/ciz1090","article-title":"Herpes zoster risk in immunocompromised adults in the United States: a systematic review","volume":"71","author":"McKay","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026070722322840300_ciaf686-B23","author":"Clinical Info HIV.gov"},{"key":"2026070722322840300_ciaf686-B24","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1093\/cid\/ciu1161","article-title":"Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort","volume":"60","author":"Grabar","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026070722322840300_ciaf686-B25","doi-asserted-by":"crossref","first-page":"e022516","DOI":"10.1136\/bmjopen-2018-022516","article-title":"AIDS Therapy Evaluation in the Netherlands (ATHENA) national observational HIV cohort: cohort profile","volume":"8","author":"Boender","year":"2018","journal-title":"BMJ Open"},{"key":"2026070722322840300_ciaf686-B26","author":"NIVEL"},{"key":"2026070722322840300_ciaf686-B27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1186\/s12913-018-3529-4","article-title":"Trends in healthcare utilization and costs associated with pneumonia in the United States during 2008\u20132014","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"2026070722322840300_ciaf686-B28","author":"Gezondheidsraad"},{"key":"2026070722322840300_ciaf686-B29","doi-asserted-by":"crossref","first-page":"e020528","DOI":"10.1136\/bmjopen-2017-020528","article-title":"Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the clinical practice research datalink 2000\u20132012","volume":"8","author":"Yanni","year":"2018","journal-title":"BMJ Open"},{"key":"2026070722322840300_ciaf686-B30","doi-asserted-by":"crossref","first-page":"e8896","DOI":"10.1371\/journal.pone.0008896","article-title":"Bacterial pneumonia among HIV-infected patients: decreased risk after tobacco smoking cessation. ANRS CO3 Aquitaine Cohort, 2000\u20132007","volume":"5","author":"Benard","year":"2010","journal-title":"PLoS One"},{"key":"2026070722322840300_ciaf686-B31","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0002-9343(01)00703-3","article-title":"Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection","volume":"110","author":"Domingo","year":"2001","journal-title":"Am J Med"},{"key":"2026070722322840300_ciaf686-B32","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1086\/515019","article-title":"High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors","volume":"27","author":"Martinez","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2026070722322840300_ciaf686-B33","doi-asserted-by":"crossref","first-page":"100576","DOI":"10.1016\/j.eclinm.2020.100576","article-title":"Immunogenicity of pneumococcal vaccination in HIV infected individuals: a systematic review and meta-analysis","volume":"29\u201330","author":"Garrido","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2026070722322840300_ciaf686-B34","doi-asserted-by":"crossref","first-page":"106629","DOI":"10.1016\/j.ijantimicag.2022.106629","article-title":"Immunogenicity of the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine in people living with HIV on combination antiretroviral therapy","volume":"60","author":"Garcia Garrido","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2026070722322840300_ciaf686-B35","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study","volume":"211","author":"Berkowitz","year":"2015","journal-title":"J Infect Dis"},{"key":"2026070722322840300_ciaf686-B36","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.vaccine.2017.12.061","article-title":"Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74\u202fyears of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"key":"2026070722322840300_ciaf686-B37","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/annonc\/mdy117","article-title":"Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors\u2014guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)","volume":"29","author":"Rieger","year":"2018","journal-title":"Ann Oncol"},{"key":"2026070722322840300_ciaf686-B38","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s10096-014-2067-1","article-title":"The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review","volume":"33","author":"Torres","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026070722322840300_ciaf686-B39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s15010-023-02070-3","article-title":"Pathogen spectrum of community acquired pneumonia in people living with HIV (PLWH) in the German CAPNETZ-Cohort","volume":"52","author":"Schleenvoigt","year":"2024","journal-title":"Infection"},{"key":"2026070722322840300_ciaf686-B40","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/cid\/ciae393","article-title":"Community-acquired pneumonia in people with HIV during the current era of effective antiretroviral therapy: a multicenter retrospective cohort study","volume":"80","author":"Bai","year":"2025","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf686\/65944506\/ciaf686.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/6\/997\/65944506\/ciaf686.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/6\/997\/65944506\/ciaf686.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:32:49Z","timestamp":1783477969000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/6\/997\/8382687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12,18]]},"published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf686","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,15]]},"published":{"date-parts":[[2025,12,18]]}}}